International Medical Research Frontier

Objective To explore the value of ursodeoxycholic acid combined with mosapride in the treatment of bile reflux gastritis and evaluate its application value. Methods according to the inclusion and exclusion criteria of the study, 80 patients with bile reflux gastritis diagnosed and treated in the hospital from January 2021 to December 2021 were included in the study, numbered 1-80. They were divided into two groups by numerical grouping method, with 40 cases in each group. The control group received mosapride single drug treatment scheme, and the experimental group received ursodeoxycholic acid and Mosapride combined treatment scheme. The symptom disappearance time of the two groups were compared The effective rate of treatment and adverse drug reactions. Results after the implementation of different drug treatment schemes, the disappearance time of abdominal distension, nausea, vomiting and other symptoms in the experimental group was significantly shorter than that in the control group, the treatment efficiency was higher, and the recurrence rate of the disease after treatment was lower. The difference was statistically significant (p<0.05); There was no significant difference between the two groups in the risk data of related adverse reactions after receiving different treatments (p>0.05). Conclusion the combined use of ursodeoxycholic acid and mosapride in the treatment of bile reflux gastritis can effectively control the symptoms of patients, enable patients to recover as soon as possible, raise the overall treatment effect to a new level, and reduce the recurrence rate of patients. At the same time, the combined treatment scheme is safe and has clinical value.

Patella fracture; Postoperative dysfunction; Physiotherapy